Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
AssigneeG1 Therapeutics, Inc.
InventorsJay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Life of this patent
Estimating the term…
Abstract
This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.
Claims14
A method of reducing ionizing radiation induced apoptosis in hematopoietic stem cells and/or progenitor cells (HSPCs) in a human exposed to ionizing radiation, the method comprising administering to the human an effective amount of a CDK4/6 inhibitor compound having the structure:
- or its pharmaceutically acceptable salt, wherein the CDK4/6 inhibitor compound is administered up to about 24 hours after exposure to the ionizing radiation.
A method for reducing the effect of ionizing radiation exposure on cyclin-dependent kinase 4 (CDK4) replication-dependent hematopoietic stem cells and/or progenitor cells (HSPCs) in a human receiving ionizing radiation for the treatment of a CDK4/6 replication independent cellular proliferation disorder, the method comprising administering to the human an effective amount of a CDK4/6 inhibitor compound having the structure:
- or its pharmaceutically acceptable salt;
- wherein the CDK4/6 inhibitor is administered less than about 4 hours prior to receiving ionizing radiation.
A method of reducing ionizing radiation induced apoptosis in cyclin-dependent kinase 4 (CDK4) replication-dependent hematopoietic stem cells and/or progenitor cells (HSPCs) in a human exposed to ionizing radiation, the method comprising administering to the human an effective amount of a CDK4/6 inhibitor compound having the structure:
- or its pharmaceutically acceptable salt, wherein the CDK4/6 inhibitor compound is administered up to about 24 hours after exposure to the ionizing radiation.
A method for reducing the effect of ionizing radiation exposure on cyclin-dependent kinase 4 (CDK4) replication-dependent hematopoietic stem cells and/or progenitor cells (HSPCs) in a human receiving ionizing radiation for the treatment of a CDK4/6 replication independent cellular proliferation disorder, the method comprising administering to the human an effective amount of a CDK4/6 inhibitor compound having the structure:
- or its pharmaceutically acceptable salt;
- wherein the CDK4/6 inhibitor is administered less than about 4 hours prior to receiving ionizing radiation.
Dependencies are inferred from the claim text.